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Are skeletally mature female rats a 
suitable model to study osteoporosis?
Ratas esqueleticamente maduras são um modelo 
satisfatório para estudar osteoporose?
Claudia Cardoso Netto1, Vivian Cristine Correia Vieira1, 
Lizanka Paola Figueiredo Marinheiro2, Sherry Agellon3, 
Hope Weiler3, Mário Roberto Maróstica Jr.1
ABSTRACT
Objective: To analyze if female Wistar rats at 56 weeks of age are a suitable model to study os-
teoporosis. Materials and methods: Female rats with 6 and 36 weeks of age (n = 8 per group) 
were kept over a 20-week period and fed a diet for mature rodents complete in terms of Ca, 
phosphorous, and vitamin D. Excised femurs were measured for bone mass using dual-energy 
x-ray absorptiometry, morphometry, and biomechanical properties. The following serum mar-
kers of bone metabolism were analyzed: parathyroid hormone (PTH), osteocalcin (OC), osteo-
protegerin (OPG), receptor activator of nuclear factor κappa B ligand (RANKL), C-terminal pep-
tides of type I collagen (CTX-I), total calcium, and alkaline phosphatase (ALP) activity. Results: 
Rats at 56 weeks of age showed important bone metabolism differences when compared with 
the younger group, such as, highest diaphysis energy to failure, lowest levels of OC, CTX-I, 
and ALP, and elevated PTH, even with adequate dietary Ca. Conclusion: Rats at 26-week-old 
rats may be too young to study age-related bone loss, whereas the 56-week-old rats may be 
good models to represent the early stages of age-related changes in bone metabolism. Arq Bras 
Endocrinol Metab. 2012;56(4):259-64
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ReSUMO
Objetivo: Avaliar se ratas Wistar com 56 semanas de idade são um modelo satisfatório para es-
tudar osteoporose. Materiais e métodos: Ratas com 6 e 36 semanas de idade (n = 8 por grupo) 
foram criadas por um período de 20 semanas e alimentadas com dieta completa em Ca, fósforo 
e vitamina D para ratas adultas. Os fêmures foram analisados quanto à massa óssea pela téc-
nica de absortiometria por dupla fonte de raios-X, morfometria e propriedades biomecânicas; 
os marcadores séricos do metabolismo ósseo analisados foram paratormônio (PTH), osteocal-
cina (OC), osteoprotegerina (OPG), fator receptor ativador nuclear κappa B ligante (RANKL), 
peptídeos C-terminal de colágeno tipo I (CTX-I), cálcio total e atividade da fosfatase alcalina 
(FA). Resultados: As ratas com 56 semanas de vida apresentaram uma importante diferença no 
metabolismo ósseo quando comparadas ao grupo das ratas jovens, como, por exemplo, maior 
energia para quebrar a diáfise do fêmur, menores níveis de OC, CTX-I e ALP e maiores níveis 
de PTH mesmo com dieta adequada em cálcio. Conclusão: As ratas com 26 semanas de vida 
podem ser consideradas muito jovens para estudar a perda óssea relacionada à idade, porém, 
as ratas com 56 semanas de vida podem representar um bom modelo dos estágios iniciais das 
alterações associadas à idade no metabolismo ósseo. Arq Bras Endocrinol Metab. 2012;56(4):259-64
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INTRODUCTION
Life expectancy in industrialized nations continues to increase, raising concerns over various health is­
sues related to aging. It is estimated that, in the next 30 
years, the proportion of people over the age of 65 years 
will double from 12% to 22%­25% of the population in 
the USA and Canada (1). Similarly, in Europe, it is es­
timated that this age group exceeds one in every thou­
sand people, and will grow from 21.4 million in year 
2000 to 35.7 million in year 2025. The most dramatic 
population growth is in the oldest age group, over 80 
years of age, and is mainly represented by women. In 
Europe, for example, there are 15.2 million women 
aged 80 years old and above, compared with only 6.2 
million men; this age group has virtually doubled from 
7.2 million women and 3.3 million men since 1970 (2).
Estrogen metabolism is extremely important for the 
regulation of bone metabolism (3,4). With the aging 
of the female population around the world, and conse­
quently prolonged deficiency of this hormone with me­
nopause, the prevalence of osteopenia and osteoporosis 
is expected to increase markedly (2). Owing to the rapid 
decline in estrogen with menopause, rates of bone loss 
accelerate during menopausal years, resulting in accele­
rated rates of osteoporosis. After the menopausal years, 
the rate of bone loss in women slows slightly and beco­
mes more comparable with that seen in older men (5).
According to a WHO Study Group, by the age of 
75 years, approximately 30% of Caucasian women may 
be classified as having osteoporosis. This is related to 
declining BMD at the femoral neck, which is predictive 
of fractures with severe clinical consequences (1,2). 
The rat is commonly used in osteoporosis research. 
In comparison with human studies, rat studies are easily 
controlled, provide rapid results due to the short life 
span of the animals, and enable access to the skeleton. 
The adult rat skeleton has many similarities with the 
human skeleton. The long bones of both species elon­
gate by epiphyseal growth (endochondral ossification) 
and increase in cross­sectional area by periosteal gro­
wth (secondary intramembranous ossification). Radial 
growth slows to very low rates in adult rats, as it does 
in humans. The secondary spongiosa in rats undergoes 
sequential remodeling, similar to that observed in hu­
man cancellous bone (6).
Despite the similarity between human and rat bone 
metabolism, studies to prevent, manage, and analyze 
osteopenia and osteoporosis mechanisms have focused 
heavily on the relatively young ovariectomized (OVX) 
rat model (7,8), rather than aged or skeletally mature 
female rats. Thus, the objective of this study was to 
analyze if skeletally mature female Wistar rats at 56 
weeks of age are suitable models to study natural oste­
oporosis caused by aging.
MATeRIAlS AND MeTHODS
Animals and diets
Female Wistar rats at 6 and 36 weeks of age (n = 8 
per group), weighing approximately 250 g and 350 g, 
respectively, were obtained from the Multidisciplinary 
Center for Biological Research at the Universidade Es­
tadual de Campinas (Unicamp, Campinas, São Paulo, 
Brazil). Animals were housed individually in stainless 
steel hanging cages at controlled temperature (21­
24˚C) and humidity (55%), and with a 12:12h light:dark 
cycle throughout the study. Animals were kept over a 
20­week period, during which they were fed ad libitum 
a nutritionally complete diet for mature rodents based 
on the AIN­93M formulation (9), containing the re­
commended amounts of Ca (5 g/kg of diet), phospho­
rous (3 g/kg of diet), and vitamin D (1000 U/kg of 
diet, Table 1). At the end of the study, animals were 26 
(n = 8) and 56 (n = 8) weeks of age. The protocol of 
this study was approved by Animal Experimental Ethics 
Committee of the Universidade Estadual de Campinas.
Tissue collection
All animals were killed by decapitation, and trunk 
blood samples were collected and stored on ice until 
Table 1. Diets formulated based on the AIN-93M (9)
Ingredients (g/kg of diet)
Cornstarch 465.692
Casein (≥ 85% protein) 140.000
Dextrinized cornstarch (90%-94% tetrasaccharides) 155.000
Sucrose 100.000
Soybean oil 40.000
Cellulose 50.000
Mineral mix (AIN-93M-MX) 35.000
Vitamin mix (AIN-93-VX) 10.000
L-Cystine 1.800
Choline bitartrate (41.1% choline) 2.500
Tert-butylhydroquinone 0.008
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they were centrifuged to obtain serum (3,000 rpm/10 
min; FANEM Excelsa Baby I – model 206/São Pau­
lo – Brazil). Serum samples were stored at ­80˚C un­
til analysis. Femur and tibia were excised and stored at 
­20˚C until analysis.
Dual-energy x-ray absorptiometry scans (DXA)
The right femur (whole femur, hip axis, and diaphysis) 
was scanned for bone area (BA), bone mineral content 
(BMC), and bone mineral density (BMD) in a water 
bath using DXA (4500A; Hologic Inc., Bedford, MA, 
USA; small animal software in high resolution mode 
QDR 12.3) (10). Precision errors (%) for triplicate 
scans of BA, BMC, and BMD were 25.6, 24.3, and 
6.1, respectively, for the whole femur; 6.1, 6.2, and 6.0, 
respectively, for the hip axis; and, 3.9, 4.7, and 5.6, res­
pectively, for the femur diaphysis.
Bone morphometry
After DXA analysis, right and left femurs were thorou­
ghly cleaned of soft tissue. Morphometric measures 
were taken with a digital caliper, as described elsewhere 
(10), and recorded to the nearest 0.01 mm. All measu­
res were recorded in triplicate by the same trained exa­
miner, and included length, and head, neck, hip axis, 
diaphysis, and distal epiphysis width. 
Biomechanical properties
The right femur diaphysis was selected to represent cor­
tical bone, which is known as a site of bone loss caused 
by aging (11). Biomechanical properties included ener­
gy to failure (N), maximum load (N), resilience (x10­3J), 
and stiffness (x103 N/m). Tests were conducted using 
a three­point bending rheolometer (Hydraulic Equip­
ment Service, INC.; 810 TestStar II MTS; Houston, 
Texas/USA), as described elsewhere (8). Measurement 
conditions were the following: sample space, 18 mm; 
plunger speed, 2 mm/min; and load range, 100 kN. 
Serum markers of bone metabolism
Serum parathyroid hormone (PTH), osteocalcin (OC), 
osteoprotegerin (OPG), receptor activator of nuclear 
factor κappa B ligand (RANKL), and C­terminal pepti­
des of type I collagen (CTX­I) were measured by enzy­
me­linked immunosorbent assays specific for rats (Rat 
Bone Panel 3 – PTH and Osteocalcin; Rat Bone Pa­
nel 1 – osteoprotegerin; Rat Bone Panel 2 – RANKL, 
Millipore, Massachusetts, USA; CTX­I of the Immu­
nodiagnostic Systems Ltd., Arizona, USA). Serum total 
calcium and alkaline phosphatase (ALP) activity were 
measured by colorimetric method (Calcium CAT no. 
00800, Laborlab – São Paulo/Brazil; alkaline phospha­
tase activity LB 170123­800, Biodiagnostic – Paraná/
Brazil) in Beckman Coulter DU­70 spectrophotometer 
(Beckman Coulter Inc., California, USA). 
All biochemical assays were performed according 
to the manufacturer’s instructions, in duplicate. Assay 
sensitivity, and intra­assay and inter­assay coefficient of 
variation (% CV) were respectively: PTH = 0.3 pg/mL, 
3.5% CV and 8.1% CV; OC = 1.6 pg/mL, 2.9% CV 
and 4.6% CV; OPG = 2.3 pg/mL, 3.1% CV and 3.4% 
CV; RANKL = 1.1 pg/mL, 3.1% CV and 9.0 %CV; 
CTX­I = 2 ng/mL, 5.6% CV and 10.5% CV, ALP = 24 
U/I, 1.2% CV and 0.99% CV.
Statistical methods
Differences between age groups were tested using 
Student’s t­test. Criteria of normal and equal variances 
between groups were met with a level of significance of 
0.05, using GraphPad Prism 5.0 (GraphPad, Inc.; La 
Jolla, CA, USA). All data are recorded as means and 
standard errors of the mean (SEM).
ReSUlTS
Feed intake and body weight
Body weight was greater (p < 0.05) in the female rats at 
56 weeks of age than at 26 weeks of age (233.5 ± 2.5 g 
vs. 333.9 ± 0.9 g) upon arrival at the facility. Daily feed in­
take during the experiment was not different between age 
groups (26 weeks: 15.2 ± 0.6 g; 56 weeks: 15.6 ± 0.6 g). 
Bone mass (DXA) and morphometry
Femur diaphysis BA, BMC and BMD, whole femur 
BMD, hip axis BA, and femur wet weight, length, and 
head, diaphysis, and distal epiphysis width results were 
greater (p < 0.05) for female rats at 56 weeks of age than 
for female rats at 26 weeks of age (Tables 2 and 3). Ho­
wever, hip axis BMC and BMD, and neck and hip axis 
widths were not different (p > 0.05) between age groups. 
Biomechanics properties
Energy to failure (endpoint of the elastic region) was 
decreased (p < 0.05) for 56 weeks of age, while maxi­
mum load, resilience and stiffness were not different (p 
> 0.05) between the age groups (Table 4).
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Table 2. Bone area (BA), mineral content (BMC), and bone mineral density 
(BMD) of femur and mandible of female rats at 26 and 56 weeks of age
26 weeks of 
age rats
(n = 8)
56 weeks of 
age rats
(n = 8)
P value
Whole femur
 BA (cm2) 1.22 ± 0.08 1.20 ± 0.11 0.5447
 BMC (g) 0.271 ± 0.017 0.280 ± 0.023 0.1812
 BMD (g/cm2) 0.221 ± 0.004a 0.237 ± 0.004b 0.0135
Hip axis
 BA (cm2) 0.28 ± 0.008a 0.31 ± 0.003b 0.0011
 BMC (g) 0.066 ± 0.003 0.073 ± 0.002 0.0648
 BMD (g/cm2) 0.233 ± 0.005 0.236 ± 0.004 0.6492
Femur diaphysis 
 BA (cm2) 0.31 ± 0.003a 0.44 ± 0.007b < 0.0001
 BMC (g) 0.070 ± 0.002a 0.108 ± 0.002b < 0.0001
 BMD (g/cm2) 0.225 ± 0.005a 0.243 ± 0.004b 0.0062
Data are presented as means (SEM). BA: bone area; BMC: bone mineral content; BMD: bone 
mineral density. Within rows, values with different letters indicate significant differences (p < 
0.05) between the age groups.
Table 3. Morphometry measurements of femur and mandible of female 
rats 26 and 56 weeks of age
Measurements
26 weeks of 
age rats
(n = 8)
56 weeks of 
age rats
 (n = 8)
P value
Wet weight (mg) 488.4 ± 16.0a 690.3 ± 6.7b < 0.0001
Length (mm) 30.3 ± 0.2a 33.8 ± 0.2b < 0.0001
Head (mm) 3.55 ± 0.09a 3.82 ± 0.04b 0.0101
Neck (mm) 2.03 ± 0.04 2.06 ± 0.02 0.4630
Hip axis (mm) 7.45 ± 0.05 7.65 ± 0.09 0.0632
Diaphysis region (mm) 3.67 ± 0.09a 4.27 ± 0.04b < 0.0001
Distal epiphysis region 
(mm)
5.40 ± 0.05a 5.59 ± 0.05b 0.0164
Data are presented as means (SEM). Within rows, values with different letters indicate 
significant differences (p < 0.05) between the age groups.
Table 4. Biomechanical properties of femurs of female rats 26 and 56 
weeks of age 
26 weeks of 
age rats
(n = 8)
56 weeks of 
age rats
 (n = 8)
P value
Energy to failure (N) 87.3 ± 1.7a 81.3 ± 0.8b 0.0051
Maximum load (N) 95.3 ± 1.2 93.8 ± 1.1 0.3850
Resilience (x10-3J) 12.3 ± 0.7 11.6 ± 1.3 0.6757
Stiffness (x103 N/m) 330.4 ± 16.6 319.1 ± 36.3 0.5357
Data are presented as means (SEM). Within rows, values with different letters indicate 
significant differences (p < 0.05) between the age groups.
Table 5. Serum markers of bone metabolism of female rats at 26 and 56 
weeks of age 
Serum markers
26 weeks of 
age rats
(n = 8)
56 weeks of 
age rats
 (n = 8)
P value
PTH (pg/mL) 2.47 ± 0.30a 6.56 ± 0.57b < 0.0001
OC (ng/mL) 4.12 ± 0.38a 2.82 ± 0.36b 0.0275
CTX-I (ng/mL) 25.12 ± 1.86a 11.98 ± 0.50b < 0.0001
ALP (U/L) 70.56 ± 8.14a 46.22 ± 7.61b 0.0464
OPG (ng/mL) 0.39 ± 0.06a 3.03 ± 0.57b 0.0004
RANKL (pg/mL) 57.55 ± 4.31 80.63 ± 23.75 0.3551
Calcium (mg/dL) 9.66 ± 0.44 8.77 ± 0.25 0.1123
Data are presented as means (SEM). PTH: parathyroid hormone; OC: osteocalcin; OPG: 
osteoprotegerin; RANKL: receptor activator of nuclear factor κappa B ligand; CTX-I: bone-
related degradation products of C-terminal peptides of type I collagen; ALP: alkaline 
phosphatase (ALP) activity. Within rows, values with different letters indicate significant 
differences (p < 0.05) between the age groups.
Serum markers of bone metabolism
Serum PTH and OPG concentrations were greater (p < 
0.05) in rats at 56 weeks of age, and serum OC, CTX­
­I, and ALP activity were lower (p < 0.05) in the same 
animals; serum RANKL concentration, and serum to­
tal calcium were not different (p > 0.05) between the 
groups (Table 5).
DISCUSSION
By examining our DXA and morphometry bone re­
sults, we can suggest that rats at 56 weeks of age did 
not show aged cortical and cancellous bone depletion. 
Kiebzak and cols. (12) evaluated cortical (femur mi­
dshaft tissue area) and trabecular (femur distal meta­
physis tissue area) bone BMC and BMD of young (24 
weeks of age), mature adult (48 weeks of age), and se­
nescent (96 weeks of age) male and female rats. These 
investigators also concluded that cortical and trabe­
cular bone BMC and BMD, and width of the femur 
increased progressively with advancing age. However, 
maximum BMD was found in mature adult rats (48 
weeks of aged), and this value decreased slightly only 
in femurs of senescent rats (96 weeks of age). Li and 
cols. (13) showed that Sprague­Dawley female rats also 
began to show decreased cancellous bone (metaphysis 
tissue area) at 48 weeks of age.
Despite the fact that our femur diaphysis BMD va­
lues were greater (p < 0.05) in rats at 56 weeks of age, 
energy to failure (endpoint of the elastic region) of this 
bone region was lower (p < 0.05) in the same group. 
Akkus and cols. (14) also observed an age­related re­
duction on energy to failure in femur diaphysis of rats. 
These results can be explained by Ammann and Rizzo­
li (15), who stated that despite BMD being a major 
determinant of bone strength, some changes, such as 
perforation and/or disappearance of cancellous bone 
A model to study osteoporosis
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without major repercussions on BMD, could account 
for the modifications in bone strength. The cortical 
sheath is connected to cancellous bone and consists of 
interconnected rods and plates. This structure maximi­
zes strength, while minimizing weight. Loss in structu­
re occurs with advancing age, and rates of fracture also 
increase markedly with age. Thus, this result is extre­
mely important because early osteoporosis is not usually 
diagnosed and remains asymptomatic; it does not beco­
me clinically evident until fractures occur, giving rise to 
significant morbidity and some mortality (2).
As for biochemical results, serum PTH was greater 
(p < 0.05) in rats at 56 weeks of age. This hormone 
is associated with increased bone resorption: typically, 
osteoblasts and osteoclasts cells respond to serum PTH 
elevation, with the net result being increased bone re­
sorption and rapid release of Ca2+ from the bone ma­
trix (16,17). Lips (18) and Mosekilde (19) described 
that upregulation of serum PTH is directly related with 
aging in mammals. Kiebzak and cols. (20) did not show 
age­related increases in PTH levels of female rats at 24, 
48 and 96 weeks of age; however, immunoreactive PTH 
titers were slightly, but significantly, elevated when the 
data were analyzed by linear regression. In humans, Sa­
raiva and cols. (21) evaluated the PTH levels in 177 
inpatients (125 women and 52 men) with 76.6 ± 9.0 
years of age, and 243 outpatients (168 women and 75 
men) with 79.1 ± 5.9 years of age; these investigators 
showed PTH levels corresponding to secondary hyper­
parathyroidism in 61.7% of the inpatients and in 54% of 
the outpatients. Russo and cols. (22) also showed PTH 
levels as secondary hyperparathyroidism in 8% of post­
­menopausal women (n = 251) between 50­85 years of 
age. Saraiva and cols. (21) and Russo and cols. (22) did 
not show correlations between serum PTH and vitamin 
D (25OHD) levels. In our study, animals were fed a 
diet adequate in vitamin D that would support normal 
PTH metabolism.
Serum OPG level was also increased in rats at 56 
weeks of age. This result is supported by Khosla and 
cols. (24), who measured serum OPG levels in an age­
­stratified, random sample of men (n = 346 age range, 23­
90 years) and women (n = 304; age range 21­93 years), 
and showed that serum OPG levels increased with age 
in both men and women (171 ± 6 pg/mL; 134 ± 6 
pg/mL, respectively). These investigators associated 
this age­related OPG elevation as a compensatory phe­
nomenon to slow down enhanced bone resorption. 
Probably, this compensatory phenomenon occurs be­
cause OPG is a soluble factor produced by osteoblastic 
cells and it is considered a decoy receptor for RANKL. 
Indeed, OPG blocks the interaction between RANKL 
and RANK, inhibiting the terminal stage of osteoclas­
tic differentiation, and then inhibiting bone resorption. 
Furthermore, the inhibitory effect of OPG on bone re­
sorption can be explained not only as a decoy receptor 
function, but also as a modulator of RANKL half­life. 
In turn, RANKL controls the bioavailability of OPG 
and its internalization and degradation (25). In our 
study, serum RANKL level did not show age­related 
difference. However, Norian and cols. (26) described 
that RANKL may be a reliable metabolite that shows 
the state of bone metabolism only in the premenopau­
sal period.
In this study, serum calcium concentration did not 
show age­related reductions. It is important to distin­
guish this model from humans in that rats were fed a 
nutritionally complete diet throughout aging, providing 
ample amounts of calcium to sustain calcium balance 
(9). Kiebzak and cols. (20) did not show age­related 
reductions on serum calcium concentration in female 
rats with 24, 48 and 96 weeks of age, either, using ani­
mals that were also fed a diet adequate in calcium. In 
addition, Takada and cols. (23) described that serum 
calcium concentration changes only in a critical situa­
tion, such as undernutrition or hyperparathyroidism.
Serum OC, CTX­I, and ALP bone markers were 
lower with aging in this study. OC and CTX­I is a 
biomar ker of bone formation and degradation, respec­
tively, and ALP is produced by osteoblasts and is pro­
portional to bone remodeling rates (27). As the main­
tenance of bone mass depends on the balance between 
bone formation and bone resorption, these results sug­
gest that the bone remodeling slows with aging in this 
rat model. Kiebzak and cols. (20) showed that serum 
OC decreased progressively from 24 to 48 weeks of age 
(21%) and from 48 to 96 weeks of age (23%) in female 
rats; however, these investigators did not show total se­
rum alkaline phosphatase activity alteration with aging 
in the same female rats. Iida and Fukuda (28) showed 
decreased in the total ALP activity up to 36 weeks of 
age in Wistar female and male rats. 
Initially, by examining our bone DXA and mor­
phometry results, we can suggest that rats at 56 weeks 
of age are not a satisfactory model to evaluate age­re­
lated changes on bone metabolism. However, the bio­
mechanical properties and biochemical results suggest 
that these rats showed important bone metabolism 
A model to study osteoporosis
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differences when compared with the younger group; 
the physiological response to any intervention is likely 
to be different as well. For example, highest diaphy­
sis energy to failure, lowest levels of OC, CTX­I, and 
ALP, and elevated PTH even with adequate dietary Ca 
might attenuate response to interventions designed to 
limit age­related bone loss. Additionally, 26­week­old 
rats may be too young to study age­related bone loss, 
whereas the 56­week­old rat may be a good model 
to represent the early stages of age­related changes in 
bones. 
Disclosure: no potential conflict of interest relevant to this article 
was reported. 
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